The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease

Clinical Neuropharmacology

Volumn 22, Issue 4, 1999, Pages 220-225

  Schwid, Steven R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Glutamate channel blocker; Levodopa; Parkinson's disease; Pharmacokinetics; Remacemide hydrochloride

Indexed keywords

LEVODOPA; REMACEMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; VERTIGO;

ACETAMIDES; AGED; ANTIPARKINSON AGENTS; DRUG INTERACTIONS; HUMANS; LEVODOPA; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; ROC CURVE;

EID: 0342632508     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993; 329:1021-7.
2. Nutt JG. Management of parkinsonism and treatment of associated complications. Curr Opin Neurol 1995;8:327-30.
3. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993;60:243-50.
4. Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm 1995;45:187-95.
5. Greenamyre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-61.
6. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996; 39:574-8.
7. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733-88.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
9. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworth, 1989;285-309.
10. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine, and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res 1995;20:250-67.
11. Simon JP, Goetz CG, Buhrnfield C, Carvey PM. The effect of bromocriptine co-therapy on L-dopa pharmacodynamics [abstract]. Mov Disord 1990;5(suppl 1):55.
12. Rahey JM, Schwartz M, Graff E, Harsat A, Vered Y. The influence of bromocriptine on the pharmacokinetcs of L-dopa in Parkinson's disease. Clin Neuropharmacol 1991;14:514-22.
13. Bentue-Ferrer D, Allain H, Reymann JM, Saboraud O, Van den Driessche J. Lack of pharmacokinetic influence on levodopa by bromocriptine. Clin Neuropharmacol 1988;11:83-6.
14. Del Dotto P, Colzi A, Musatti E, Strolin-Benedetti M, Persiani S, Fariello R, Bonuccelli U. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clin Neuropharmacol 1997;20:455-65.
15. Kaakola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
16. Dingemanse J, Jorga K, Zurcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P. pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.